Three presentations at the ESMO Congress 2024 (Barcelona, 13–17 September) reported on therapies designed to stimulate or boost the body’s antitumour immune response in the management of aggressive, high-grade gliomas, which typically carry a poor prognosis.

Emeline Tabouret from GlioME Team discussed these data during the proffered paper session – CNS tumours reported here.